Company: NCEL
Filing Date: 2025-01-28
Form Type: 425
Source: 0001213900-25-007315
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-01-28
Form: 425
Chunk 5
---
that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the combined
company’s or NLS’s ability to have future successful meetings with the FDA; risks related to the companies' ability to complete
the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions
related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals
for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to
business relationships resulting from the announcement or completion of the proposed merger or resulting from the trial or preclinical
program and potential adverse reactions or changes to business relationships resulting from the announcement of the trial or preclinical
program; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or
successfully completing their clinical trials; the companies' products may not be approved by regulatory agencies; their technologies
may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies
may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific
difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated;
results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not
correlate with the results of human clinical trials; the companies' patents may not be sufficient; their products may harm recipients;
changes in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies,
products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results
or performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise
required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS's annual report on Form
20-F for the year ended December 31, 2023, filed with